Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 ARROW study

被引：0
|
作者：
Mateos, Maria-Victoria [1 ]
Ludwig, Heinz [2 ]
Kumar, Shaji [3 ]
Rosenbaum, Cara [4 ]
Huang, Mei [5 ]
Goldrick, Amanda [5 ]
Blaedel, Julie [5 ]
Dimopoulos, Meletios A. [6 ]
机构：
[1] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[2] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Vienna, Austria
[3] Mayo Clin, Rochester, MN USA
[4] Weill Cornell Med, New York, NY USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
carfilzomib; frailty; Relapsed Refractory MM;
D O I：
10.1016/j.clml.2019.09.047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-046
引用
收藏
页码：E31 / E32
页数：2
相关论文
共 50 条
  • [1] Safety and Efficacy of Once-Weekly Carfilzomib (K) Dosing in Frail Patients (pts): A Subgroup Analysis from the Phase 3 ARROW Study
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Kumar, Shaji
    Rosenbaum, Cara
    Huang, Mei
    Goldrick, Amanda
    Blaedel, Julie
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S320 - S321
  • [2] Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts):A subgroup analysis from the phase 3 ARROW study.
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Kumar, Shaji
    Rosenbaum, Cara Ann
    Huang, Mei
    Goldrick, Amanda
    Blaedel, Julie
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 ARROW Study (NCT02412878) By Prior Lines
    Moreau, Philippe
    Stewart, A. Keith
    Lazzaro, Antonio
    Dimopoulos, Meletios A.
    Cavo, Michele
    Ailawadhi, Sikander
    Iskander, Karim
    Huang, Mei
    Zahlten-Kumeli, Anita
    Mateos, Maria-Victoria
    BLOOD, 2018, 132
  • [4] Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (ARROW) and comparison with ENDEAVOR
    Takezako, Naoki
    Shibayama, Hirohiko
    Handa, Hiroshi
    Hagiwara, Shotaro
    Ozaki, Shuji
    Suzuki, Kenshi
    Kosugi, Hiroshi
    Ri, Masaki
    Sugiura, Isamu
    Choi, Ilseung
    Miyamoto, Toshihiro
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (02) : 219 - 230
  • [5] Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study ARROW
    Mateos, Maria-Victoria
    Moreau, Philippe
    Berenson, James R.
    Weisel, Katja
    Lazzaro, Antonio
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Huang, Mei
    Zahlten-Kumeli, Anita
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study
    Moreau, Philippe
    Mateos, Maria-Victoria
    Berenson, James R.
    Weisel, Katja
    Lazzaro, Antonio
    Song, Kevin
    Dimopoulos, Meletios A.
    Huang, Mei
    Zahlten-Kumeli, Anita
    Stewart, A. Keith
    LANCET ONCOLOGY, 2018, 19 (07): : 953 - 964
  • [7] Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)
    Moreau, Philippe
    Kumar, Shaji
    Boccia, Ralph
    Iida, Shinsuke
    Goldschmidt, Hartmut
    Cocks, Kim
    Zahlten-Kumeli, Anita
    Yucel, Emre
    Panjabi, Sumeet
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S240 - S240
  • [8] Post hoc subgroup analysis of Asian children with paediatric GHD from the global phase 3 efficacy and safety study of once-weekly somatrogon vs. once-daily somatropin
    Gomez, Roy
    Khadilkar, Vaman
    Shembalkar, Jayashri
    Chu, Der-Ming
    Ko, Cheol Woo
    Wajnrajch, Michael P.
    Wang, Ronnie
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2024, 37 (06): : 525 - 531
  • [9] Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis
    Dimopoulos, Meletios A.
    Niesvizky, Ruben
    Weisel, Katja
    Siegel, David S.
    Hajek, Roman
    Mateos, Maria-Victoria
    Cavo, Michele
    Huang, Mei
    Zahlten-Kumeli, Anita
    Moreau, Philippe
    BLOOD CANCER JOURNAL, 2020, 10 (03)
  • [10] Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR
    Naoki Takezako
    Hirohiko Shibayama
    Hiroshi Handa
    Shotaro Hagiwara
    Shuji Ozaki
    Kenshi Suzuki
    Hiroshi Kosugi
    Masaki Ri
    Isamu Sugiura
    Ilseung Choi
    Toshihiro Miyamoto
    Shinsuke Iida
    International Journal of Hematology, 2021, 113 : 219 - 230
12345